Navigation Links
Transave, Inc. Secures $12.5 Million in New Financing
Date:10/2/2008

thcare.

"This financing, in addition to a $35M Series D financing closed in March, will enable us to complete our Arikace Phase II program for the treatment of Pseudomonas infections in cystic fibrosis patients," said Tim Whitten, Transave's chief executive officer. "It also allows us to broaden the Arikace clinical trial program by initiating a Phase II clinical trial in a second area of high unmet need: bronchiectasis patients who have pseudomonas lung infections."

Based on the strength of the Arikace clinical profile to date, the company has initiated a Phase II trial to evaluate the compound for treating Pseudomonas infections in patients with non-cystic fibrosis-related bronchiectasis in Europe and India. The U.S. Food and Drug Administration (FDA) has also agreed to the company's plans to expand this trial into the United States. Bronchiectasis is the permanent widening of the bronchi (the large tubes which begin at the bottom of the trachea and branch into the lungs). Individuals with bronchiectasis are vulnerable to recurrent respiratory infections, which often have a Pseudomonas component.

Kristen Kosofsky, managing director of Horizon, noted, "Our goal at Horizon is to support the growth and success of innovative companies like Transave that develop important next-generation technologies that serve as the cornerstone for improving human health and quality of life."

About Arikace (liposomal amikacin for inhalation)

Arikace is a form of the antibiotic amikacin that is enclosed in nanocapsules of lipid called liposomes. This proprietary next-generation liposomal technology prolongs release of amikacin in the lung while minimizing systemic exposure. The treatment uses biocompatible lipids endogenous to the lung that are formulated into small (0.3 micrometers), neutrally-charged liposomes that enable biofilm penetration and are highly efficient, with very low lipid-to-drug ratio (0.65). Arikace can be effectively delivered thr
'/>"/>

SOURCE Transave, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Transave, Inc. Raises $35 Million Through Series D Convertible Preferred Stock Financing
2. Northwest Secures US$1.0 Million Debt Financing
3. Trillium secures additional financing on the strength of lead program and proprietary position around the CD200 immunoregulatory pathway
4. Althea Technologies Secures $12 M Credit Line to Continue Facility Growth and Expansion
5. Progenitor Cell Therapy Secures Industry Accreditation
6. BIOCOM Institute Secures Non-Profit Designation and Funding
7. Cara Therapeutics Secures $12.3 Million in Series C Extension Financing
8. OMTEC 2008 Boasts Record Attendance and Secures Premier Position as Must-attend for Orthopaedic Companies
9. Genta Secures Up to $40 Million Convertible Financing Facility to Fund Key Programs
10. Novasys Medical Secures $49.5 Million in Series D Financing to Expand Commercialization of Its Renessa(R) Treatment for Incontinence in Women
11. Veran Medical Technologies Secures $4.75M in First Institutional Funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , Aug. 4, 2015  Natera, Inc. (Nasdaq: ... and the analysis of circulating cell-free DNA, today announced ... ended June 30, 2015 after the market close on ... and webcast at 1:30 p.m. PT (4:30 p.m. ET) ... outlook.Event:Natera,s Second Quarter 2015 Results Conference Call  Date: , ...
(Date:8/3/2015)...  Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... quarter 2015 on Monday, August 10, 2015 at 4:30 ... president and chief executive officer, will lead the call. ... results for the second quarter 2015. The ... of Halozyme,s corporate website and a recording will be ...
(Date:8/3/2015)... UK (PRWEB) , ... August 03, 2015 , ... ... consumer of benzene. Benzene is processed to get such derivatives as ethylbenzene, a ... derivatives are principally used within the automotive industry for the production of tyres ...
(Date:8/3/2015)... , August 3, 2015 E-QURE ... commercialization of its Bio-electrical Signal Therapy device ("BST Device"), ... of hard to heal chronic wounds, today announced that ... Chemipal, an Israeli distributor specializing in medical devices, for ... Chemipal is a 70 years old, sales, marketing ...
Breaking Biology Technology:Natera to Release Second Quarter 2015 Results on August 12, 2015 2Halozyme to Host Second Quarter 2015 Financial Results Conference Call 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 3E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3
... exciting at the beginning. , ,Two companies enter into ... Web site, or have a service provider deliver a range ... work out perfectly well and the parties come to the ... has been performed or received. , ,However, sometimes the ...
...
... Fiserv Inc. has released a software suite ... , ,CRM software keeps track of the interactions between ... times, allowing the business to coordinate its customer service. ... with other systems from Fiserv, which makes a wide ...
Cached Biology Technology:Arbitration can help when IT deals go sour 2Arbitration can help when IT deals go sour 3
(Date:7/31/2015)... 2015 A 10 a. Conferência Internacional ... BGI de 22-25 de outubro de 2015, em ... está celebrando seu 10 o. aniversário este ano. Desde ... das reuniões mais influentes do mundo no ramo das ... e prazerosos. A ICG-10 se concentra ...
(Date:7/31/2015)... 2015 La 10 th International Conference on ... BGI del 22 al 25 de octubre de 2015 en ... la conferencia celebra su décimo aniversario. Desde su inauguración en ... las reuniones anuales más influyentes del mundo en el campo ... entusiastas y mejores a nivel científico. ICG-10 ...
(Date:7/31/2015)... OXFORD, Conn. , Jul. 31, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces that it has filed provisional patent 62/198989 for ... This invention highlights a method to advance crypto-currencies ... technology by introducing a common, uniform way to manage ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... at Polytechnic Institute of New York University (NYU-Poly) have ... single virus particles in solution, an advance that may ... shrink test result wait times from weeks to minutes. ... and member of the Othmer-Jacobs Department of Chemical and ...
... is largely restricted to the eastern edge of the New England Tableland, ... raised this flowering plant, until now classified as a variety of the ... of a distinct species. The study was published in the open access ... the family of flowering plants that includes the Banksia and ...
... After waking up, the concentration of the stress hormone ... only for grown-ups but for babies as well. A ... has reported this finding in the journal Psychoneuroendocrinology ... possibility to already research the activity of the stress ...
Cached Biology News:By detecting smallest virus, researchers open possibilities for early disease detection 2By detecting smallest virus, researchers open possibilities for early disease detection 3Botany student proves 'New England Banksia' a distinct species 2New method: Research team analyzes stress biology in babies 2
... adsorption and clarification reagent; Ideal for ... of antibodies, proteins, nucleic acids, & ... cross-reactivity, and improves downstream processing; Utilizes ... non-ionic adsorbent supplied as a suspension ...
... The lyophilization stabilizer is designed ... process and for long-term storage. ... toxic ingredients. It is a ... pH 7.2, and is superior to ...
... Digital shaking water bath, with a comprehensive ... and shaking water baths with seamless, splash-water ... The bright MULTI-DISPLAY (LED) indicating up to ... the lab. Advanced MICROPROCESSOR technology with PID ...
... buffered anti-freeze environment for enzyme conjugated antibodies ... low viscosity solution at -20C , ... sampling is convenient , Contains preservatives ... Protect enzyme conjugates during storage without ...
Biology Products: